Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 13,900 Shares of Revvity, Inc. (NYSE:RVTY)

Fjarde AP Fonden Fourth Swedish National Pension Fund lowered its stake in shares of Revvity, Inc. (NYSE:RVTY) by 40.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 20,740 shares of the company’s stock after selling 13,900 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Revvity were worth $2,315,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of RVTY. Gladius Capital Management LP bought a new position in Revvity during the 3rd quarter valued at about $32,000. Continuum Advisory LLC increased its position in shares of Revvity by 2,972.7% during the 3rd quarter. Continuum Advisory LLC now owns 338 shares of the company’s stock valued at $43,000 after purchasing an additional 327 shares during the last quarter. MassMutual Private Wealth & Trust FSB increased its position in shares of Revvity by 55.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company’s stock valued at $43,000 after purchasing an additional 138 shares during the last quarter. Avior Wealth Management LLC increased its position in shares of Revvity by 7,980.0% during the 3rd quarter. Avior Wealth Management LLC now owns 404 shares of the company’s stock valued at $52,000 after purchasing an additional 399 shares during the last quarter. Finally, Principal Securities Inc. increased its position in shares of Revvity by 54.9% during the 4th quarter. Principal Securities Inc. now owns 598 shares of the company’s stock valued at $67,000 after purchasing an additional 212 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

Insider Buying and Selling at Revvity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the transaction, the insider now owns 33,400 shares in the company, valued at $4,232,782. The trade was a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tajinder S. Vohra sold 5,492 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. The trade was a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.60% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RVTY shares. TD Cowen upped their price target on shares of Revvity from $141.00 to $144.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Robert W. Baird upped their price target on shares of Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Raymond James reaffirmed an “outperform” rating and set a $145.00 price target (up previously from $140.00) on shares of Revvity in a research report on Monday, February 3rd. Barclays increased their target price on shares of Revvity from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, Bank of America raised shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 target price for the company in a report on Friday, December 13th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.25.

Revvity Stock Down 0.4 %

NYSE RVTY opened at $115.00 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The company has a market capitalization of $14.00 billion, a P/E ratio of 52.04, a P/E/G ratio of 3.82 and a beta of 1.03. Revvity, Inc. has a one year low of $97.32 and a one year high of $129.50. The stock has a 50 day moving average price of $116.89 and a 200-day moving average price of $118.57.

Revvity (NYSE:RVTY) last posted its earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter in the prior year, the company posted $1.25 earnings per share. As a group, equities analysts predict that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity declared that its board has approved a share buyback program on Monday, November 4th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 6.5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity’s dividend payout ratio (DPR) is 12.67%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.